BUSINESSWEEK ONLINE : NOVEMBER 1, 1999 ISSUE
[an error occurred while processing this directive] [an error occurred while processing this directive]
INTERNATIONAL -- EUROPEAN BUSINESS What's Ailing a Giant GENE FURY Backlash over genetically modified crops is undermining the life-sciences concept upon which Novartis was created three years ago SLOW GROWTH Patent expirations, generic competition, and an aging portfolio of drugs will result in two years of single-digit growth for the core pharmaceuticals business TROUBLED AGRIBUSINESS Weak commodity prices, increased competition, and concerns over biotechnology, especially in Europe, are driving down margins and hurting sales DATA: BUSINESS WEEK _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _					RELATED ITEMS Healing Novartis (int'l edition) TABLE: What's Ailing a Giant CHART: Taking a Fall INTERACT E-Mail to Business Week Online

Copyright 1999, by The McGraw-Hill Companies Inc. All rights reserved. Terms of Use   Privacy Policy